Multimorbidity: what next?

Multimorbidity: What do we know? What should we do?

Multimorbidity, which is defined as the co-occurrence of two or more chronic conditions, has moved onto the priority agenda for many health policymakers and healthcare providers. Patients with multimorbidity are high utilizers of healthcare resources and are some of the most costly and difficult-to-treat patients in Europe. Preventing and improving the way multimorbidity is managed is now a key...

where do we stand and what comes next?

Pharmacogenomics: What is Next?

Pharmacogenomics is moving from a candidate gene strategy to large scale approaches. This is in line with the new paradigm of linking a trait to (a) pathway(s) rather than to single genes. In addition, breakthroughs in genomics offer a non-a priori assessment of implicated genes, expanding the possibilities in pharmacogenomics research. In this review, we discuss the pros and cons of new concep...

What ’ s next ?

Collections of cultural heritage documents are most of the time digitized images. These precious documents are now available on the internet and need manual annotations to make their content accessible and exploitable. Manual annotations are expensive and tedious; hence the use of a collaborative annotation space and the reuse of users’ experiences, by tracing their actions -during the annotati...

What Next after Anonymity?

In recent years, interest has shifted from protecting the confidentiality of data to protecting the confidentiality of metadata. The police often learn more from traffic analysis than from content interception; thus anonymity becomes more important than confidentiality in the classical sense. Many researchers have been working with systems such as remailers and Tor in order to provide anonymity...